Indian Journal of Nuclear Medicine
Home | About IJNM | Search | Current Issue | Past Issues | Instructions | Ahead of Print | Online submissionLogin 
Indian Journal of Nuclear Medicine
  Editorial Board | Subscribe | Advertise | Contact
Users Online: 726 Print this page  Email this page Small font size Default font size Increase font size

    Article Cited by others

ORIGINAL ARTICLE

Response assessment in metronomic chemotherapy: RECIST or PERCIST?

Agrawal Archi, Purandare Nilendu, Shah Sneha, Puranik Ameya, Banavali Shripad, Rangarajan Venkatesh

Year : 2014| Volume: 29| Issue : 2 | Page no: 74-80

   This article has been cited by
 
1 Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM)
Laura Orlando, Vito Lorusso, Francesco Giotta, Massimo Di Maio, Paola Schiavone, Palma Fedele, Annamaria Quaranta, Chiara Caliolo, Mariangela Ciccarese, Margherita Cinefra, Sante Romito, Salvatore Pisconti, Salvatore del Prete, Michele Aieta, Daniele Rizzi, Evaristo Maiello, Giuseppe Colucci, Saverio Cinieri
The Breast. 2020; 53: 18
[Pubmed]  [Google Scholar] [DOI]
2 Comparison between RECIST and PERCIST criteria in therapeutic response assessment in cases of lymphoma
Marwa Mohammed Hasan Tawfik, Ahmed Mohamed Monib, Aya Yassin, Susan Adil Ali
Egyptian Journal of Radiology and Nuclear Medicine. 2020; 51(1)
[Pubmed]  [Google Scholar] [DOI]
3 Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review
Seon Jeong Min, Hyun Joo Jang, Jung Han Kim
Oncotarget. 2016; 7(19): 27848
[Pubmed]  [Google Scholar] [DOI]

 

Read this article